Let's spread some joy this summer with a lemonade stand that gives back!
Celebrate National Lemonade Day this August and host a lemonade stand with your kids to support bladder cancer patients nationwide.
Encourage entrepreneurship and creativity in your children while supporting patients and funding innovative research and new treatments for cancer patients.
Let's squeeze out some smiles and make a real difference together! 🙌
Snap a pic and tag us! 📸
|
|
|
|
|
Walk, run, bike, swim, or roll and support the bladder cancer community. Register today to participate this September and help us reach 13,400 km, the number of Canadians diagnosed with bladder cancer annually.
Let us know how many kms you cover, download the STRAVA app.
Step out anytime and anywhere this September!
Join our national challenge today!
|
|
Join the 12in1 League and become a monthly donor! |
Just $20 a month allows Bladder Cancer Canada to provide Educational Resources to bladder cancer patients across Canada in English, French, Punjabi, Spanish, Hindi, and Chinese.
|
|
|
Bladder Cancer Basics: Essential Knowledge for Patients and Caregivers
Tuesday, September 17 at 7pm ET

Join us for an informative webinar offering a comprehensive overview of bladder cancer. Hosted by Dr. Paul Toren, this session will cover key aspects of the disease, including risk factors, symptoms, diagnosis, staging, grading, and treatment options for various types of bladder cancer.
Whether you're newly diagnosed or caring for someone with bladder cancer, this webinar will equip you with the essential knowledge to navigate a bladder cancer diagnosis.
|
|
Understanding Urinary Diversions: Options, Outcomes, and Living Well 
Tuesday, October 8 from 7:00-8:15pm ET
Join us for an informative webinar exploring the various urinary diversions available to individuals undergoing a radical cystectomy. This session, hosted by Leah Jamnicky, a nurse with over 38 years’ experience in the Division of Urology, will provide an in-depth look at the different options, discussing the pros and cons of each.
You'll also gain valuable tips and tricks for managing daily life with a urinary diversion. Additionally, you will hear firsthand experiences from individuals living with each type of diversion, offering unique insights and practical advice.
|
|
Winnipeg Bladder Cancer Education Event
Tuesday, October 22 from 6:00-9:00pm ET
Join us for a free in-person educational event in Winnipeg on Tuesday, October 22. The evening features a presentation on muscle-invasive bladder cancer by Dr. Jay Nayak, and on non-muscle invasive bladder cancer by Dr. Ardalan Ahmad.
Seats are limited, so register today to secure your spot!
|
|
Thanks to our sponsors: Verity Pharmaceutical |
|
For upcoming events, webinars, support group meetings and more, visit our Events Page
|
|
|
|
Catch up on latest Content |
|
Immune reprogramming and response to BCG therapy in patients with bladder cancer |
|
Bacillus Calmette-Guérin (BCG) immunotherapy has been the gold standard for treating high-risk non-muscle invasive bladder cancer (NMIBC) patients for over 50 years. However, patients’ response to BCG varies, making it challenging to predict individual outcomes. Recent research suggests that trained immunity (TI) in peripheral blood monocytes, induced by BCG, could serve as a biomarker for predicting treatment response and recurrence-free survival.

TI is a long-lasting memory in innate immune cells, triggered by inflammatory stimuli like BCG. It involves metabolic and epigenetic reprogramming of cells such as monocytes, macrophages, and dendritic cells. Studies have shown that higher levels of TI, indicated by increased IL-12 secretion, are associated with patients without recurrence. Additionally, distinct epigenetic changes, specifically histone modifications, were observed in monocytes from patients with different recurrence outcomes, which could be leveraged to predict responses to BCG therapy. To further investigate the trends in transcriptomic and epigenetic profiles of peripheral blood mononuclear cells from NMIBC patients after BCG therapy, researchers plan to use single-cell RNA sequencing (scRNAseq) and ATAC-seq platform to elucidate the link between immune reprogramming and treatment response. Overall, trained immunity induced by BCG may offer a promising biomarker for predicting treatment outcomes in NMIBC patients.
|
|
Walk with us at one of our local Locations
We are thrilled to announce the list of confirmed walk locations for the 2024 edition of Canada Walks to End Bladder Cancer! Full details can be found on our Find a Walk page. We look forward to walking with you!
|
|
Boost Your Impact with DOMO Gasoline! |
The first 200 donations of $100 or more will receive a $100 donation match by Domo Gasoline Corporation Ltd.
|
|
|
Participate in a new study…
|
|
Are you newly diagnosed with invasive bladder cancer or scheduled for bladder removal surgery? Participate in our study to help us understand how bladder cancer affects quality of life and the treatment decision process. Participants will be asked to complete questionnaires over 12 months, sharing their experiences. |
|
|
|
Your input will improve care for bladder cancer patients and help shape future supportive care programs.
Join us and help improve patient care!
Ready to get involved?
|
|
If you would be interested in learning more about this or other studies
and/or want to share your story with other bladder cancer patients,
|
|
Have you been treated with pembro (Keytruda) alone or in combination with Padcev (Enfortumab vedotin) and are interested in sharing your story? Contact Marilou today!
|
|
|
|
We are looking for volunteers to join our team! |
|
|
|
Would you like to volunteer at
Canada Walks for Bladder Cancer?
|
We are currently recruiting volunteers to help at Canada Walks for Bladder Cancer events across the country! |
Contact Theresa today to get involved!
|
|
|
|
Please join us on social media where we share updates and photos from our bladder cancer community. These social media sites are a great resource for patients, survivors, and caregivers. |
|
Copyright © 2024 Bladder Cancer Canada. All rights reserved. You are receiving this email because you have registered on our website or expressed an interest in receiving more information about bladder cancer or Bladder Cancer Canada. |
|
|
|
|
|
|
‌
‌
‌
‌
‌